Director, stem cell transplant program Huntsville hospital
Oncology
Dr. Jeremy K. Hon, MD
|
|
Give Review
Jeremy works in the field of Oncology. He went to University of Alabama School of Medicine. University of Alabama School of Medicine has a rank of 37 in research and a 17 in primary care He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Jeremy is also a published doctor. He has 12 publication published. The most recent publication is: One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicentre, phase II trial. Jeremy K. Hon, MD accepts Medicare.
Publications
- Patient-Reported Neuropathy and Taxane-Associated Symptoms in a Phase 3 Trial of nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin for A...
- Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic Leukemia and small lymphocytic lymphoma.
- Long-term follow-up of patients treated with paclitaxel/carboplatin-based chemotherapy for advanced non-small-cell lung Cancer: sequential phase II trials of the Minni...
- Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled Analysis of two randomized, controlled clinical trials.
- Rapid in vitro assay for predicting response to fluorouracil in patients with metastatic breast Cancer.
- Mucormycosis: a community hospital perspective.
- One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung Cancer: results of a multicentre, phase II trial.
- Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung Cancer.
- Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung Carcinoma.
- Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl Cancer research network phase II trial.
- Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Schools
University Of Alabama School Of Medicine
University Tex Health Science Center
University Tex Health Science
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Texas Health Science Center -
University of Alabama School of Medicine
Drug Facts
| NPI NUMBER | 1295714384 | |
| NPPES Provider LastName | HON | |
| NPPES Provider FirstName | JEREMY | |
| NPPES Provider ZIPCode | 358052606 | |
| NPPES Provider State | AL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 2832.0 | |
| Distinct Opioid Count | 9.0 | |
| Opioid Claim Count | 403.0 | |
| Percent Opioid Claims | 14.23 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1295714384 |
| Last Name Of The Provider | HON |
| First Name Of The Provider | JEREMY |
| View All |
Similar Doctors
|
|
Dr. Ali B. Hachem, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Manh C. Dang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marshall T. Schreeder, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. John Waples, MD
This Doctor is OpenDoctor Recommended.
|